Jointown Pharmaceutical Group Co., Ltd. Jointown Pharmaceutical Group Co., Ltd.

Jointown Pharmaceutical Group Co., Ltd.

600998

Rank in Stocks #4326
Jointown Pharmaceutical Group Co., Ltd engages in pharmaceutical distribution... Jointown Pharmaceutical Group Co., Ltd engages in pharmaceutical distribution and supply chain business in China and internationally. It is also involved in general agency brand promotion; pharmaceutical industrial self-production and OEM; and pharmaceutical new retail and ten-thousand store alliance plan businesses. In addition, the company provides medical health and technology value-added services; and digital logistics and supply chain solutions. The company was founded in 1999 and is headquartered in Wuhan, China.
Share Price
$0.72312028
Market Cap
$3.65B
Change (1 day)
0.40%
Change (1 year)
3.84%
Country
CN
Trade Jointown Pharmaceutical Group Co., Ltd. (600998)

Category

Healthcare
Revenue for Jointown Pharmaceutical Group Co., Ltd. (600998)
Revenue in Jun 2026 TTM: $24.28B
According to Jointown Pharmaceutical Group Co., Ltd. latest financial reports the company's current revenue (TTM) is $24.28B. In 2023 the company made a revenue of $21.21B an increase over the revenue in the year 2022 that was $20.36B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Jointown Pharmaceutical Group Co., Ltd. from 2007 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $24.28B 16.75%
2024 $20.80B -1.94%
2023 $21.21B 4.19%
2022 $20.36B 5.70%
2021 $19.26B 13.49%
2020 $16.97B 18.76%
2019 $14.29B 12.80%
2018 $12.67B 11.46%
2017 $11.36B 28.18%
2016 $8.87B 16.10%
2015 $7.64B 15.17%
2014 $6.63B 20.28%
2013 $5.51B 16.50%
2012 $4.73B 20.10%
2011 $3.94B 22.37%
2010 $3.22B 15.95%
2009 $2.78B 16.33%
2008 $2.39B 33.57%
2007 $1.79B 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$410.98B 1,592.53%
US
- -
US
$254.25B 947.05%
US
- -
US
$7.64B -68.53%
AU